Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ko, G. T.
Right arrow Articles by Cockram, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ko, G. T.
Right arrow Articles by Cockram, C. S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 8 1221-1225, Copyright © 1998 by American Diabetes Association


ARTICLES

Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects

GT Ko, JC Chan, VT Yeung, CC Chow, LW Tsang, JK Li, WY So, HP Wai and CS Cockram
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong, China.

OBJECTIVE: To assess the validity of using fasting plasma glucose (FPG) concentrations in conjunction with HbA1c or fructosamine for the screening of diabetes in high-risk individuals. RESEARCH DESIGN AND METHODS: In this study 2,877 Hong Kong Chinese (565 [19.6%] men; 2,312 [80.4%] women) with various risk factors for glucose intolerance underwent a 75-g oral glucose tolerance test (OGTT) for screening of diabetes. The risk factors included a family history positive for diabetes, a history of gestational diabetes or impaired glucose tolerance, and obesity. RESULTS: Using World Health Organization (WHO) criteria, 1,593 (55.4%) had normal glucose tolerance, 657 (22.8%) had impaired glucose tolerance, and 627 (21.8%) had diabetes. When the 1997 American Diabetes Association (ADA) criteria were applied, 394 (13.7%) had diabetes with an FPG > or = 7.0 mmol/l. Using multiple receiver operating characteristic curve analysis, the paired values of an FPG of 5.6 mmol/l and a HbA1c of 5.5% gave an optimal sensitivity of 83.8% and specificity of 83.6% to predict a 2-h plasma glucose (PG) > or = 11.1 mmol/l. Likewise, the paired values of an FPG of 5.4 mmol/l and a fructosamine level of 235 mumol/l (n = 2,408) gave an optimal sensitivity of 81.5% and specificity of 83.2%. An FPG > or = 5.6 mmol/l and an HbA1c > or = 5.5% was 5.4-fold more likely to occur in diabetic subjects (based on the WHO criteria) compared with nondiabetic subjects. For paired parameters less than these values, the likelihood ratio of this occurring in diabetic subjects was only 0.11. Similarly, an FPG > or = 5.4 mmol/l and a fructosamine > or = 235 mumol/l was fivefold more likely to occur in diabetic subjects than in nondiabetic subjects, with both parameters less than these values having a likelihood ratio of 0.04. Using these paired values as initial screening tests, only subjects who had an FPG > or = 5.6 mmol/l and < 7.8 mmol/l and an HbA1c > or = 5.5% (n = 642) required an OGTT to confirm diabetes, thereby saving 77.7% [(2,877-642)/2,877] of the OGTTs performed. Similarly, only subjects who had an FPG > or = 5.4 mmol/l and < 7.8 mmol/l and a fructosamine > or = 235 mumol/l (n = 526) required OGTT to confirm diabetes, meaning that 78.2% [(2,408-526)/2,408] of the OGTTs could have been saved. Based on the 1997 ADA criterion of an FPG cutoff value of 7.0 mmol/l, the corresponding numbers of OGTTs to be saved were 82.6% and 85.5%, respectively. CONCLUSIONS: The paired values of FPG and HbA1c or FPG and fructosamine helped to identify potentially diabetic subjects, the diagnosis of which could be further confirmed by the 75-g OGTT. Using this approach approximately 80% of OGTTs could have been saved, depending on the diagnostic cutoff value of FPG.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann Clin BiochemHome page
T. Likhari, T S Aulakh, B. M Singh, and R Gama
Does HbA1C predict isolated impaired fasting glycaemia in the oral glucose tolerance test in subjects with impaired fasting glycaemia?
Ann Clin Biochem, July 1, 2008; 45(4): 418 - 420.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. Doi, M. Kubo, T. Ninomiya, K. Yonemoto, M. Iwase, H. Arima, J. Hata, Y. Tanizaki, M. Iida, and Y. Kiyohara
Impact of Kir6.2 E23K Polymorphism on the Development of Type 2 Diabetes in a General Japanese Population: The Hisayama Study
Diabetes, November 1, 2007; 56(11): 2829 - 2833.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Bergeron, J. Yao, J. W. Woods, E. I. Zycband, C. Liu, Z. Li, A. Adams, J. P. Berger, B. B. Zhang, D. E. Moller, et al.
Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Agonism Prevents the Onset of Type 2 Diabetes in Zucker Diabetic Fatty Rats: A Comparison with PPAR{gamma} Agonism
Endocrinology, September 1, 2006; 147(9): 4252 - 4262.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
J. E. Shaw, P. Z. Zimmet, and K. G. M.M. Alberti
Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion
Diabetes Care, May 1, 2006; 29(5): 1170 - 1172.
[Full Text] [PDF]


Home page
Clin. DiabetesHome page
Expert Committee on the Diagnosis and Classificati
Follow-up Report on the Diagnosis of Diabetes Mellitus
Clin. Diabetes, April 1, 2004; 22(2): 71 - 79.
[Full Text] [PDF]


Home page
Diabetes CareHome page
S. Colagiuri, Z. Hussain, P. Zimmet, A. Cameron, and J. Shaw
Screening for Type 2 Diabetes and Impaired Glucose Metabolism: The Australian experience
Diabetes Care, February 1, 2004; 27(2): 367 - 371.
[Abstract] [Full Text] [PDF]


Home page
Diabetes Spectr.Home page
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Spectr, January 1, 2004; 17(1): 51 - 59.
[Full Text] [PDF]


Home page
Diabetes CareHome page
The Expert Committee on the Diagnosis and Classifi
Follow-up Report on the Diagnosis of Diabetes Mellitus
Diabetes Care, November 1, 2003; 26(11): 3160 - 3167.
[Full Text] [PDF]


Home page
Diabetes CareHome page
S. S. Anand, F. Razak, V. Vuksan, H. C. Gerstein, K. Malmberg, Q. Yi, K. K. Teo, and S. Yusuf
Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population
Diabetes Care, February 1, 2003; 26(2): 290 - 296.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
U. Krishnamurti and M. W. Steffes
Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus
Clin. Chem., July 1, 2001; 47(7): 1157 - 1165.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
R. C. Perry, R. R. Shankar, N. Fineberg, J. McGill, and A. D. Baron
HbA1c Measurement Improves the Detection of Type 2 Diabetes in High-Risk Individuals With Nondiagnostic Levels of Fasting Plasma Glucose: The Early Diabetes Intervention Program (EDIP)
Diabetes Care, March 1, 2001; 24(3): 465 - 471.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.